基本情報
- CAS
8065-29-0- 標準SMILES
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+].[Na+]- InChIKey
LKYWLLWWYBVUPP-XOCLESOZSA-L- 分子式
- C30H21I7N2Na2O8
- 平均分子量
- 1,471.8 g/mol
- 単同位体質量
- 1,471.4406
概要
Liotrix is a phenylalanine derivative.
名称と識別子
- 優先名称
- Liotrix
- IUPAC
- disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
- 現地名
- リオトリックス
- 英語名
- (2S)-2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propanoate
- 分子式
- C30H25I7N2Na2O8
- 分子量
- 1475.85
名称と別名
LiotrixEuthroidThyrolar8065-29-0Liotrix (T4;T3)YW8HJ0N26XDTXSID401001390RefChem:153586DTXCID301428341disodium (2S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoate (2S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoateNovothyralCombithyrex
名称をさらに表示
リオトリックスレボチロキシンナトリウム?リオチロニンナトリウムレボチロキシンナトリウム・リオチロニンナトリウム(2S)-2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propanoate(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]propanoatedisodium:(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate:(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoateDiotroxinLiotrix [USAN:USP]Liothyronine Sodium and Levothyroxine SodiumUNII-YW8HJ0N26XW 1782CHEBI:6485SCHEMBL15569465
物性
構造計算による物性
- 極性表面積
- 191 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 10
- 回転可能結合数
- 8
- 重原子数
- 49
- 形式電荷
- 0
- 複雑度
- 811
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Thyroid Hormones
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
毒性情報
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
化学と産業
薬理情報
Pharmacodynamics
Thyroid hormone drugs are natural or synthetic preparations containing T<sub>4</sub> or T<sub>3</sub> or both. T<sub>4</sub> and T<sub>3</sub> are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. Liotrix is a synthetic preparation of T4 and T3 in a 4:1 weight-based ratio. These hormones enhance oxygen consumption by most tissues of the body and increase the basal metabolic rate and the metabolism of carbohydrates, lipids and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system.
Mechanism of Action
The hormones, T<sub>4</sub> and T<sub>3</sub>, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major secreted form of thyroid hormone is T4. T4 is converted T3, the more active thyroid hormone, by deiodinases in peripheral tissues. T3 acts in the body to increase basal metabolic rate, alter protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). Thyroid hormones are essential for proper development and differentiation of all cells of the human body. T<sub>4</sub> and T<sub>3</sub> regulate protein, fat and carbohydrate metabolism to varying extents. The most pronounced effect of the hormones is in altering how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects.
FDA Pharmacological Classification
YW8HJ0N26X
LIOTRIX
Established Pharmacologic Class [EPC] - l-Thyroxine
Established Pharmacologic Class [EPC] - l-Triiodothyronine
Chemical Structure [CS] - Thyroxine
Chemical Structure [CS] - Triiodothyronine
Absorption, Distribution and ExcretionThyroid hormones are primarily eliminated by the kidneys.
応用分野
使用Thyroid hormone.
サプライヤー
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…